Dean L. Schorno serves as the Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals Inc., a biotechnology company focused on discovering, developing, and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. In his role, Schorno is responsible for overseeing the financial strategy and operations of the company, ensuring its fiscal health and guiding its growth trajectory. His strategic financial leadership is crucial in navigating the complex landscape of pharmaceutical development and commercialization. Schorno brings a wealth of experience to Rigel Pharmaceuticals, having held senior financial positions at several prominent companies in the life sciences sector. Prior to joining Rigel, he served as the Chief Financial Officer at Anacor Pharmaceuticals, where he played a pivotal role in leading the company through its initial public offering and subsequent growth phases. His expertise in financial management, coupled with his deep understanding of the biotech industry, has been instrumental in driving Rigel's financial performance and strategic initiatives. Schorno's career also includes significant stints at other notable organizations such as Cell Genesys and Chiron Corporation, where he honed his skills in corporate finance and strategic planning. Under Schorno's leadership, Rigel Pharmaceuticals has seen steady progress in its financial stability and operational efficiency. His contributions have been vital in securing funding for the company's research and development efforts, as well as in forging strategic partnerships that enhance Rigel's market position. Schorno's ability to balance short-term financial needs with long-term strategic goals has made him an invaluable asset to Rigel, helping the company to advance its mission of delivering innovative therapies to patients in need.